Article Compendium Resource Guide Table of Contents Manuscript

Front Cover Title:	Article Compendium Resource Guide
Disclaimer:	Do not detail from this binder.
Spine:	Article Compendium Resource Guide
Cover Graphic:	((Clinical look and feel))
Table of Contents Page:	TABLE OF CONTENTS
Headline:	TABLE OF CONTENTS
Subhead:	Core Messages:
Item Name & Topic: Status & Number: Citation:	ALM Reprint Safety, Efficacy DETAIL XL217613 Alm A, Schoenfelder J, McDermott J. A 5-year, multicenter, open-label, safety study of adjunctive latanoprost therapy for glaucoma. Arch Ophthalmol. 2004; 122:957-965.
Item Name & Topic: Status & Number: Citation:	Camras Reprint Efficacy OFF-LABEL XL843088 Camras CB, and the United States Latanoprost Study Group. Comparison of latanoprost and timolol in patients with ocular hypertension and glaucoma: a six-month, masked, multicenter trial in the United States. Ophthalmology. 1996;103:138-147.
Item Name & Topic: Status & Number: Citation:	Dasgupta Persistency DETAIL Available in supplement XL186292123 Dasgupta S, Oates V, Bookhart BK, Vaziri B, Schwartz GF, Mozaffari E. Population-based persistency rates for topical glaucoma medications measured with pharmacy claims data. Am J Manag Care. 2002;8(suppl):S255-S261.
Item Name & Topic: Status & Number: Citation:	Netland Efficacy, Tolerability DETAIL Not Available Netland PA, Landry T, Sullivan EK, et al, and the Travoprost Study Group. Travoprost compared with latanoprost and timolol in patients with open-angle glaucoma or ocular hypertension. Am J Ophthalmol. 2001;132:472-484
Item Name & Topic: Status & Number: Citation:	Netland Response Tolerability DETAIL Not Available Netland PA, Landry T, Sullivan EK, et al. Travoprost compared with latanoprost and timolol in patients with open-angle glaucoma or ocular hypertension [author reply]. Am J Ophthalmol. 2002;133:732-733.
Item Name & Topic: Status & Number: Citation:	Noecker Efficacy, Tolerability DETAIL Not Available Noecker RS, Dirks MS, Choplin NT, Bernstein P, Batoosingh AL, Whitcup SM, for the Bimatoprost/Latanoprost Study Group. A six-month randomized clinical trial comparing the intraocular pressure-lowering efficacy of bimatoprost and latanoprost in patients with ocular hypertension or glaucoma. Am J Ophthalmol. 2003;135:55-63.
Item Name & Topic: Status & Number: Citation:	Parrish XLT Reprint Efficacy, Tolerability DETAIL XL143293 Parrish RK, Palmberg P, Sheu W-P, for the XLT Study Group. A comparison of latanoprost, bimatoprost, and travoprost in patients with elevated intraocular pressure: a 12-week, randomized, masked-evaluator multicenter study. Am J Ophthalmol. 2003;135:688-703.
Item Name & Topic: Status & Number: Citation:	Reardon Persistency DETAIL Available in supplement XL194406 Reardon G, Schwartz GF, Mozaffari E. Patient persistency with topical ocular hypotensive therapy in a managed care population. Am J Ophthalmol. 2004;137(suppl):S3-S11.
Subhead:	Landmark Studies & Discussions
Item Name: Status & Number: Citation:	AGIS DETAIL Not Available AGIS Investigators. The Advanced Glaucoma Intervention Study (AGIS): 7. The relationship between control of intraocular pressure and visual field deterioration. Am J Ophthalmol. 2000;130:429-440.
Item Name: Status & Number: Citation:	CIGTS DETAIL XL220294 Janz NK, Wren PA, Lichter PR, Musch DC et al and the CIGTS Study Group. The collaborative initial glaucoma treatment study. Interim quality of life findings after initial medical or surgical treatment of glaucoma. Ophthalmology. 2001;108:1954-1963.
Item Name: Status & Number: Citation:	Heijl Reprint OFF-LABEL XL845757 Heijl A, Leske MC, Bengtsson B, Hyman L, Bengtsson B, Hussein M, for the Early Manifest Glaucoma Trial Group. Reduction of intraocular pressure and glaucoma progression: results from the Early Manifest Glaucoma Trial. Arch Ophthalmol. 2002;120:1268-1279.
Item Name: Status & Number: Citation:	EMGT Leske DETAIL Not Available Leske MC, Heijl A, Hussein M, Bengtsson B, Hyman L, Komaroff E, for the Early Manifest Glaucoma Trial Group. Factors for glaucoma progression and the effect of treatment: the Early Manifest Glaucoma Trial. Arch Ophthalmol. 2003;121:48-56.
Item Name: Status & Number: Citation:	Kass OHTS Reprint OFF-LABEL XL843097 Kass MA, Heuer DK, Higginbotham EJ, et al, for the Ocular Hypertension Treatment Study Group. The Ocular Hypertension Treatment Study: a randomized trial determines that topical ocular hypotensive medication delays or prevents the onset of primary open-angle glaucoma. Arch Ophthalmol. 2002;120:701-713.
Item Name: Status & Number: Citation:	Palmberg Reprint DETAIL XL845704 Palmberg P. Answers from the ocular hypertension treatment study. Arch Ophthalmol. 2002;120:829-830.
Item Name: Status & Number: Citation:	LALES DETAIL (XL to come) The Los Angeles Latino Eye Study. Design, methods, and baseline data. Ophthalmology. 2004;111:1121-1131
Subhead:	Other Supporting Studies
Item Name & Topic: Status & Number: Citation:	Davies Reprint HYD Mode of Action DETAIL XL138903 Davies SS, Ju WK, Neufeld AH, Abran D, et al. Hydrolysis of bimatoprost (lumigan) to its free acid by ocular tissue in vitro. J Oc Pharm Ther. 2003;19: 45-54
Item Name & Topic: Status & Number: Citation:	Fechtner Reprint Efficacy, Tolerability DETAIL XL208939 Fechtner RD, Airaksinen J, Getson aJ, Lines CR, Adamsons IA on behalf of the COSOPT versus XALATAN Study Groups. Acta Ophthalmologica Scandinavica. 2004;82:42-48.
Item Name & Topic: Status & Number: Citation:	FURUICHI Reprint Safety OFF-LABEL XL843026 Furuichi M, Chiba T, Abe K, Kogure S, et al. Cystoid macular edema associated with topical latanoprost in glaucomatous eyes with a normally functioning blood-ocular barrier. J Glaucoma. 2001;10:233-236.
Item Name & Topic: Status & Number: Citation:	BMJ Kirwan Reprint Safety DETAIL XL845746 Kirwan JF, Nightingale JA, Bunce C, Warmald R. b Blockers for glaucoma and excess risk of airways obstruction: population based cohort study. BJM. 2002; 325:1396-1397.
Item Name & Topic: Status & Number: Citation:	Linden Reprint with WLF disclaimer Dosing Effect WLF XL190780 Linden C, Nuija E, Alm A. Effects on IOP restoration and blood-aqueous barrier after long term treatment with latanoprost in open angle glaucoma and ocular hypertension. Brit J Ophthalmol. 1997;81:370-372.
Item Name & Topic: Status & Number: Citation:	Weinreb Reprint Efficacy DETAIL XL220297 Liu JH, Kripke DF, Weinreb RN. Comparison of the nocturnal effects of once-daily timolol and latanoprost on intraocular pressure. Am J Ophthalmol. 2004; ARTICLE IN PRESS-VOLUME AND PAGE NUMBERS NOT AVAILABLE.
Item Name & Topic: Status & Number: Citation:	Schwartz Clin Ther Reprint Persistancy DETAIL XL149681 Reardon G, Schwartz GF, Mozaffari E. Patient persistency with ocular prostaglandin therapy: a population-based, retrospective study. Clin Ther. 2003;25:1172-1185.
Item Name & Topic: Status & Number: Citation:	Sponsel Reprint Efficacy OFF-LABEL XL843068 Sponsel WE, Paris G, Trigo Y, Pena M, et al. Latanoprost and brimonidine: therapeutic and physiologic assessment before and after oral nonsteroidal anti-inflammatory therapy. Am J Ophthalmol. 2002;133:11-18.
Item Name & Topic: Status & Number: Citation:	Stewart Reprint Persistancy DETAIL (XL to come) A persistency and economic analysis of latanoprost, bimatoprost or beta-blockers in patients with open-angle glaucoma or ocular hypertension. J Ocul Pharmacol Ther 2004. ARTICLE IN PRESS, VOLUME AND PAGE NUMBER UNAVAILABLE.
Item Name & Topic: Status & Number: Citation:	Toris Reprint Mode of Action DETAIL XL845717 Toris CB, Koepsell SA, Yablonski ME, Camras CB. Aqueous humor dynamics in ocular hypertensive patients. J Glaucoma. 2002;11:253-258.
Item Name & Topic: Status & Number: Citation:	AJO Risk Article Risk Assessment FYI (XL to come) Weinreb RN, Friedman DS, Fechtner RD, Cioffi GA, et al. Risk Assessment in the management of patients with ocular hypertension. Am J Ophthalmol. 2004; 138. ARTICLE IN PRESS-NO PAGE NUMBER AVAILABLE.
Subhead:	Supplements
Item Name: Status & Number: Citation:	Am J Ophthalmol. 2004;138 Supplement FYI XL220720 AJO Risk Supplement
Item Name: Status & Number: Citation:	Am J Ophthalmol 2004;137 Supplement DETAIL XL194406 AJO Schwartz Supplement
Item Name: Status & Number: Citation:	AJMC Supplement DETAIL XL186292 Am J Manag Care. 2002;8 Supplement
TAB TAB TAB TAB	CORE MESSAGES LANDMARK STUDIES OTHER SUPPORTING STUDIES SUPPLEMENTS
Signoff on BACK PAGE:	XL212239 © 2004 Pfizer Inc. All rights reserved. Printed in USA/ September, 2004 [[Pfizer Ophthalmics logo]] [[Pfizer logo]]